Spanish Academy of Dermatology and Venereology (AEDV) Melanoma Registry
ConditionMelanoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorFundación Academia Española de Dermatología
About this trial
The goal of this patient registry is to describe risk factors for bad prognosis of melanoma in Spain. The main questions it aims to answer are:
* To describe socioeconomical individual risk factors associated with melanoma prognosis, such as gender, residence area or socioeconomic level. * To describe potentially modifiable characteristics of health care associated with prognosis, such as waiting times, type of centre that makes the diagnosis or use of teledermatology Participants data will be gathered for analysis, without any change in the way that they are being treated.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
All consecutive patients with a diagnosis of invasive primary cutaneous melanoma in participating centres.
Disqualifiers
In-situ melanomas
non-cutaneous melanomas,
metastatic melanoma with unknown primary site.
Trial population
All consecutive patients with a diagnosis of invasive primary cutaneous melanoma in participating centres.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
AJCC (American Joint Committee on Cancer) TNM stage (Tumor, node, metastasis)
Staging based on tumor thickness and ulceration, spread to lymph nodes and spread to distant sites.
Time frame
1 day At diagnosis2
Breslow thickness
Breslow thickness is the measurement of the depth of the melanoma from the surface of your skin down through to the deepest point of the tumour.
Time frame
1 day At diagnosisSecondary outcomes
1
Time to progression
Time frame
through study completion, an average of 3 years2
Survival
Time frame
through study completion, an average of 3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov